Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate (CR011-vcMMAE) targeting GPNMB

@article{Pollack2007TreatmentPM,
  title={Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate (CR011-vcMMAE) targeting GPNMB},
  author={Vincent A. Pollack and Enrique Alvarez and Kam Fai Tse and Michael Y. Torgov and Sam Xie and Suresh Shenoy and John R Macdougall and Sharon Arrol and Haihong Zhong and Robert W. Gerwien and William F. Hahne and Peter D. Senter and Michael E. Jeffers and Henri S. Lichenstein and William J. Larochelle},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2007},
  volume={60},
  pages={423-435}
}
To investigate the pharmacological properties of the CR011-vcMMAE fully human antibody–drug conjugate (ADC), such as dose titrations, quantitation of the time (days) to complete regression, pharmacokinetics, and schedule dependency. Our prior study characterized a fully human antibody to GPNMB covalently linked to monomethylauristatin E, CR011-vcMMAE, and further demonstrated cell surface staining of melanoma lines susceptible to the immunoconjugate’s cytotoxicity (Clin Cancer Res 2005; 12(4… CONTINUE READING